RapidPulse

Medtech · Neurovascular Devices · Medical Devices

Funding

RapidPulse raises $48M Series B with Medtronic backing stroke device

The financing funds a pivotal trial that could determine whether faster clot removal becomes the new standard for stroke care.

• RapidPulse closed an oversubscribed $48 million Series B financing co-led by Medtronic, TechWald Next S.p.A., and S3 Ventures to advance its stroke aspiration device.
• The Miami-based medtech company is developing a proprietary aspiration system that uses controlled cyclic suction to improve clot engagement and removal during mechanical thrombectomy for acute ischemic stroke.
• The capital will fund completion of RapidPulse's TURBO trial, an FDA investigational device exemption study testing pulsed aspiration for reperfusion of brain occlusions across US and European stroke centers.
• Positive TURBO data could support RapidPulse's first FDA regulatory submission for its full line of aspiration catheters.
• Mechanical thrombectomy, the procedure RapidPulse's device supports, is a minimally invasive technique in which catheters are guided through blood vessels to physically remove clots blocking blood flow to the brain.
• Medtronic's direct investment in a private stroke-device rival signals how established device makers are hedging against next-generation thrombectomy technology outpacing their own portfolios.